Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 6/20 | 0.84 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | MAOA | P21397 | 1/20 | 0.84 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.84 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimobendan SCHEMBL14815175 | 1.00 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL27623 | 1.00 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL15617988 | 1.00 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL2466855 | 1.00 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL668129 | 0.99 | PDE3B (0.83) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1996787 | 0.99 | PDE3B (0.83) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1997246 | 0.98 | PDE3B (0.81) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1993626 | 0.95 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1649737 | 0.92 | PDE3B (1.00) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781454 | 0.87 | PDE3B (0.64) | PDE3BPDE3AABCB11MAOAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719429-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-3865120-B1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-06-25 | — | — | EP | claimed |
| CN-113056465-B | Tetrahydropyrane (THP) -substituted bicyclic pyrimidinedione compounds | 迈奥卡迪亚公司 | 2025-01-28 | — | — | CN | claimed |
| WO-2024240632-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-11-28 | — | — | WO | claimed |
| CN-118382694-A | Methods and compositions for generating human erythroid progenitors | 特雷尔赫德生物系统股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| EP-4376830-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-3439660-B1 | USE OF PIMOBENDAN FOR THE REDUCTION OF HEART SIZE AND THE DELAY OF ONSET OF CLINICAL SYMPTOMS IN PATIENTS WITH ASYMPTOMATIC HEART FAILURE DUE TO MITRAL VALVE DISEASE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-05-01 | — | — | EP | claimed |
| CN-115267000-B | Method for detecting acardi new stimulant | 吴昕辰 | 2024-03-19 | — | — | CN | claimed |
| EP-2793866-B2 | BILAYER TABLET COMPRISING BENAZEPRIL HYDROCHLORIDE AND PIMOBENDAN | ELANCO TIERGESUNDHEIT AG (CH) | 2023-10-25 | — | — | EP | claimed |
| EP-3389638-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PIMOBENDAN | CEVA SANTE ANIMALE (FR) | 2023-08-02 | — | — | EP | claimed |
| CN-116114549-A | Cold-proof cultivation method for bananas in field | 广西壮族自治区农业科学院 | 2023-05-16 | — | — | CN | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| WO-2023006747-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | claimed |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-10-27 | — | — | US | claimed |
| EP-4054588-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-04-07 | — | — | US | claimed |
| CN-122056207-A | High-efficiency okra cultivation method | 福建省农业科学院作物研究所(福建省种质资源中心) | 2026-05-19 | — | — | CN | disclosed |
| CN-122042838-A | Application of gestational late urine metabolic marker of gestational diabetes and kit | 上海市第一人民医院 | 2026-05-15 | — | — | CN | disclosed |
| US-11246867-B2 | Pharmaceutical composition comprising pimobendan | CEVA SANTE ANIMALE (FR) | 2022-02-15 | — | — | US | disclosed |
| WO-2022027180-A1 | APPLICATION OF PHOSPHODIESTERASE INHIBITOR OR PHARMACEUTICAL COMPOSITION THEREOF IN PREPARATION OF DRUG FOR TREATING NOVEL CORONAVIRUS PNEUMONIA | 南方科技大学 | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | PDE3B 172/4885PDE3A 103/4885ABCB11 1734/4885 |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | PDE3B 172/4885PDE3A 103/4885ABCB11 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.